Birmingham/Atlanta VA Geriatric Research, Education, and Clinical Center, Atlanta VA Health System, Atlanta, Georgia.
Division of General Medicine & Geriatrics, Department of Medicine, Emory University, Decatur, Georgia.
Neurourol Urodyn. 2019 Aug;38(6):1737-1744. doi: 10.1002/nau.24052. Epub 2019 Jun 11.
Determine the efficacy of behavioral therapy for urinary symptoms in Parkinson's disease.
Randomized trial of behavioral therapy compared with control condition among adults (aged 54-85 years, 74% male, 10% Black/ 83% White) with Parkinson's and greater than or equal to 4 incontinence episodes weekly. Behavioral therapy included pelvic floor muscle exercises, bladder training, fluid and constipation management. Both groups completed bladder diary self-monitoring. Outcomes included diary-derived incontinence and ICIQ-overactive bladder (OAB) score (range, 0-16) with bother and quality of life questionnaires (higher scores = worse outcomes).
Fifty-three participants randomized and 47 reported 8-week outcomes including 26 behavioral therapy and 21 control. Behavioral vs control participants were similar with respect to age (71.0 ± 6.1 vs 69.7 ± 8.2 years), sex (70% vs 78% male), motor score, cognition, mean weekly incontinence episodes (13.9 ± 9.6 vs 15.1 ± 11.1) and OAB symptoms (8.9 ± 2.4 vs 8.3 ± 2.2). Weekly incontinence reduction was similar between behavioral (-6.2 ± 8.7) and control participants (-6.5 ± 13.8) (P = 0.89). After multiple imputation analysis, behavioral therapy participants reported statistically similar reduction in OAB symptoms compared to control (-3.1 ± 2.8 vs -1.9 ± 2.2, P = 0.19); however quality of life (-22.6 ± 19.1 vs -7.0 ± 18.4, P = 0.048) and bother (-12.6 ± 17.2 vs - 6.7 ± 8.8, P = 0.037) improved significantly more with behavioral therapy.
Self-monitoring resulted in fewer urinary symptoms; however, only multicomponent behavioral therapy was associated with reduced bother and improved quality of life. Providers should consider behavioral therapy as initial treatment for urinary symptoms in Parkinson's disease.
确定行为疗法对帕金森病患者泌尿系统症状的疗效。
对 54-85 岁(74%为男性,10%为黑人/83%为白人)、每周至少出现 4 次失禁的成年帕金森病患者进行行为疗法与对照条件的随机试验。行为疗法包括盆底肌锻炼、膀胱训练、液体和便秘管理。两组均完成膀胱日记自我监测。结果包括日记中记录的失禁和国际尿失禁咨询问卷(overactive bladder,OAB)评分(范围为 0-16,得分越高表示结果越差),以及困扰和生活质量问卷。
53 名参与者被随机分配,47 名参与者报告了 8 周的结果,其中包括 26 名行为疗法组和 21 名对照组。行为疗法组和对照组在年龄(71.0±6.1 岁 vs 69.7±8.2 岁)、性别(70% vs 78%为男性)、运动评分、认知、每周平均失禁次数(13.9±9.6 次 vs 15.1±11.1 次)和 OAB 症状(8.9±2.4 次 vs 8.3±2.2 次)方面相似。行为疗法组(-6.2±8.7)和对照组(-6.5±13.8)的每周失禁减少量相似(P=0.89)。在多次插补分析后,与对照组相比,行为疗法组 OAB 症状的改善更为显著(-3.1±2.8 次 vs -1.9±2.2 次,P=0.19);然而,生活质量(-22.6±19.1 分 vs -7.0±18.4 分,P=0.048)和困扰(-12.6±17.2 分 vs -6.7±8.8 分,P=0.037)显著改善。
自我监测可减少泌尿系统症状,但只有多组分行为疗法与减少困扰和改善生活质量有关。因此,对于帕金森病患者的泌尿系统症状,临床医生应首先考虑行为疗法。